Clinuvel Pharmaceuticals Limited (ASX:CUV)
Australia · Delayed Price · Currency is AUD | Market Cap | 460.41M -13.3% |
| Revenue (ttm) | 96.30M +5.8% |
| Net Income | 32.54M -16.1% |
| EPS | 0.64 -16.3% |
| Shares Out | 50.43M |
| PE Ratio | 14.18 |
| Forward PE | 12.33 |
| Dividend | 0.05 (0.56%) |
| Ex-Dividend Date | Sep 4, 2025 |
| Volume | 117,064 |
| Average Volume | 120,087 |
| Open | 9.11 |
| Previous Close | 8.98 |
| Day's Range | 8.98 - 9.27 |
| 52-Week Range | 8.57 - 14.00 |
| Beta | 0.68 |
| RSI | 43.78 |
| Earnings Date | Feb 26, 2026 |
About Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a... [Read more]
Financial Performance
In fiscal year 2025, Clinuvel Pharmaceuticals's revenue was 95.02 million, an increase of 7.76% compared to the previous year's 88.18 million. Earnings were 36.17 million, an increase of 1.50%.
Financial StatementsNews
CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study
EXECUTIVE SUMMARY final European scientific advice received for pivotal Phase III vitiligo study EMA emphasised its “totality of evidence” approach central photographic review and validated disease as...
CLINUVEL: advancing peptides for photomedicine and vitiligo care at AAD 2026
MELBOURNE, Australia, April 15, 2026 (GLOBE NEWSWIRE) -- CLINUVEL's innovative photomedicine and vitiligo programs featured extensively at the recent American Academy of Dermatology (AAD) Annual Meeti...
Clinuvel Pharmaceuticals Earnings Call Transcript: H1 2026
Revenue grew 4% year-over-year to a record high, with profitability maintained despite a 22% rise in expenses driven by R&D and expansion. Cash reserves reached AUD 233 million, supporting self-funded growth and upcoming catalysts like clinical trial readouts and Nasdaq listing.
CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies
EXECUTIVE SUMMARY VALLAURIX Research, Development & Innovation Centre to expand its existing facilities and capabilities core focus on accelerating development of liquid long-acting drug delivery plat...
CLINUVEL to advance novel pharmaceutical formulations in preclinical program
Next generation sustained-release formulations for a variety of peptides Next generation sustained-release formulations for a variety of peptides
Clinuvel Pharmaceuticals Earnings Call Transcript: H2 2025
Reported ninth consecutive annual profit with 10% revenue growth to $105M and a 34% net margin. Cash reserves rose 22%, supporting robust R&D and expansion, while the EPP and vitiligo markets continue to grow. Major clinical and regulatory milestones are expected in the coming year.
CLINUVEL preparing upgrade of ADR program to Level II, Nasdaq uplist
Executive summary plan to upgrade American Depository Receipt (ADR) program (CLVLY) to a Level II ADR listed on Nasdaq, expected before the end of 2025 CLINUVEL's primary listing on the ASX will remai...
CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105
CLINUVEL has met its recruitment target in its phase III trial (CUV105) of SCENESSE® (afamelanotide 16mg) in vitiligo, with more than 200 patients enrolled
Clinuvel Introduces Groundbreaking Vitiligo Program at the World's Biggest Dermatology Meeting, AAD 2025
MELBOURNE, Australia, March 03, 2025 (GLOBE NEWSWIRE) -- World-leading photomedicine company CLINUVEL will make its début at the American Academy of Dermatology (AAD) Annual Meeting from March 7–11, w...
Clinuvel Pharmaceuticals Earnings Call Transcript: H1 2025
Half-year results showed strong revenue and profit growth, with robust cash reserves and continued expansion in key markets. Investment in late-stage clinical programs is set to rise, while a prudent capital management approach supports future growth and resilience.
Clinuvel Pharmaceuticals Transcript: AGM 2024
The meeting highlighted record financial results, board renewal, and strategic expansion into new therapies and photocosmetics. Key challenges include CEO succession, clinical trial completion, and leveraging strong cash reserves for growth.
CLINUVEL files Canadian New Drug Submission for SCENESSE® in EPP
MELBOURNE, Australia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- CLINUVEL has filed a New Drug Submission (NDS) to Health Canada, seeking approval for its novel photoprotective therapy SCENESSE® (afamelanotide...
Clinuvel Pharmaceuticals Earnings Call Transcript: H2 2024
Record revenue and profit were achieved, driven by Scenesse demand and expansion in key markets. Strong margins, robust cash reserves, and a debt-free balance sheet support ongoing R&D, new product launches, and a continued share buyback program.
Afamelanotide in fair-skinned Parkinson's patients
MELBOURNE, Australia, June 18, 2024 (GLOBE NEWSWIRE) -- CLINUVEL today announced a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson's Disease (PD or Parkinson's)...
Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE® (afamelanotide...
Malibu shines a light on CLINUVEL's pioneering work in photomedicine
MALIBU, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Leading biotech company CLINUVEL last week joined an intimate event bringing together California's most prolific investors and philanthropists at the...
Clinuvel Pharmaceuticals Earnings Call Transcript: H1 2024
Clinuvel Pharmaceuticals Transcript: Status Update
Clinuvel Pharmaceuticals Earnings Call Transcript: H2 2023
CLINUVEL Launches CYACÊLLE, Next Generation Solar Care
UV, HEV protection for individuals at high risk of photoageing and skin cancer
Global SCENESSE® demand drives increased CLINUVEL revenues, earnings
MELBOURNE, Australia, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Executive summary Positive Results in the Half Year to 31 December 2022
CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals
Study in healthy volunteers shows single dose of afamelanotide reduces erythema caused by ultraviolet radiation Study in healthy volunteers shows single dose of afamelanotide reduces erythema caused b...
CLINUVEL Trial Results Show Drug Reduces DNA Damage
Results in “children of the moon” disorder have implications for populations at highest risk of skin cancer Results in “children of the moon” disorder have implications for populations at highest risk...
Clinuvel Pharmaceuticals Earnings Call Transcript: H2 2022
CLINUVEL progresses vitiligo treatment program
Novel approach to addressing pigment loss disorder affecting an estimated 45 million individuals worldwide Novel approach to addressing pigment loss disorder affecting an estimated 45 million individu...